The use of soluble ACE2 to counteract pulmonary damage has been studied in two phase-II trials involving acute lung injury or acute respiratory distress syndrome, and pulmonary arterial hypertension. The gene discussed is ACE2; the disease is pulmonary arterial hypertension.